Enovis vs Smith & Nephew
ENOV and SNN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENOV and SNN compare
Smith & Nephew grew revenue faster over the last twelve months (6.1% versus 3.3% for Enovis).
Enovis scores higher on the StockData Score (7 against 6 for Smith & Nephew), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENOV | SNN |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | – |
| Share price | $27.68 | $31.28 |
| Change, 1 year | −11.4% | −6.5% |
| Change, 5 years | −81.7% | −9.7% |
| Beta (5Y) | 1.14 | 0.62 |
| Employees | 7,802 | 18K |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 1 |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.7× | – |
| P/B | 1.1× | – |
| EV/EBITDA | 3.3× | – |
| P/FCF | 22.9× | – |
| FCF yield | 4.4% | – |
| Growth | ||
| Revenue growth (TTM) | 3.3% | 6.1% (better) |
| Revenue growth, 5Y average | 14.9% (better) | 6.2% |
| EPS growth (TTM) | – | 52.3% |
| EPS growth, 5Y average | – | 6.9% |
| Profitability | ||
| Gross margin | 61.3% | 68.0% (better) |
| Operating margin | −20.6% | 12.9% (better) |
| Net margin | −22.9% | – |
| FCF margin | 3.0% | – |
| Return on equity | −30.0% | – |
| Return on invested capital | −12.3% | 13.0% (better) |
| Financial health | ||
| Debt / equity | 0.84 | 0.10 (better) |
| Net debt / EBITDA | 1.43 (better) | −0.31 |
| Interest coverage | −14.7× | 5.7× (better) |
| Current ratio | 2.15 (better) | 2.14 |
| Altman Z-score | 0.29 | – |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 122% | 4.2% |
| Held by insiders | 2.7% | 25.1% |
| Insider net buying, 12 months | $792K | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 18.8% | – |
Go deeper
- ENOV stock overview
- ENOV income statement
- ENOV valuation and score
- SNN stock overview
- SNN income statement
- SNN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.